NuCana plc - American Depositary Share (NCNA) News
Filter NCNA News Items
NCNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NCNA News Highlights
- NCNA's 30 day story count now stands at 3.
- Over the past 24 days, the trend for NCNA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest NCNA News From Around the Web
Below are the latest news stories about NUCANA PLC that investors may wish to consider to help them evaluate NCNA as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWelcome back and get ready for another day of trading with a breakdown of the biggest pre-market stock movers for Monday! |
Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana’s ‘190 Patent is Not ValidRuling Has No Impact on NuCana’s Anti-Cancer ProTide PatentsMUNICH, Germany, March 24, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a hearing on March 24, 2023, the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) issued an oral judgement that NuCana’s European Patent 2955190 (the “’190 patent”) is not valid. The TBA reversed the previous decisions of the EPO’s Examination Division which issued NuCana’s ‘190 patent and of the EPO’s O |
We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayThe biggest pre-market stock movers are making waves on Wednesday with huge gainers and losers worth watching this morning! |
NuCana to Participate in Two Upcoming Investor ConferencesEDINBURGH, United Kingdom, Feb. 28, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in two upcoming investor conferences. Event: Cowen’s 43rd Annual Healthcare Conference Presentation Date: Tuesday, March 7, 2023Presentation Time: 10:30 AM ET Event: Oppenheimer's 33rd Annual Healthcare Conference Presentation Date: Tuesday, March 14, 2023Presentation Time: 12:40 PM ET The pres |
NuCana Regains Compliance with Nasdaq Minimum Bid Price RequirementEDINBURGH, United Kingdom, Jan. 23, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) and the matter is |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! |
NuCana Announces Receipt of NASDAQ NoticeEDINBURGH, United Kingdom, Jan. 06, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated January 3, 2023, indicating that, based upon a closing bid price of less than $1.00 per share for the Company’s American Depositary Shares (“ADSs”) for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5450(a)(1). The Notification Letter h |
NuCana to Host Investor Meetings During the J.P. Morgan Healthcare ConferenceEDINBURGH, United Kingdom, Jan. 03, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that management will host one-on-one meetings during the 41st Annual J.P. Morgan Healthcare Conference, January 9 – 12, 2023 in San Francisco. About NuCanaNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleo |
NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |